Lumos Pharma Return On Capital Employed Over Time
| LUMO Stock | USD 4.32 0.02 0.47% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lumos Pharma Performance and Lumos Pharma Correlation. Lumos |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Return On Capital Employed Analysis
Compare Lumos Pharma and related stocks such as Pardes Biosciences, Shattuck Labs, and Eliem Therapeutics Return On Capital Employed Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STTK | (0.13) | (0.13) | (0.13) | (0.13) | (0.13) | (0.13) | (0.13) | (0.13) | (0.13) | (1.0033) | (0.1112) | (0.1652) | (0.5729) | (0.6209) | (0.65) |
| CSBR | 0.1042 | (2.6382) | (0.7338) | (1.202) | (1.6044) | (21.9023) | (12.0727) | (2.2718) | 0.0833 | (0.1694) | 0.0206 | 0.0339 | (0.3537) | (1.6023) | (1.68) |
| IPSC | (2.7983) | (2.7983) | (2.7983) | (2.7983) | (2.7983) | (2.7983) | (2.7983) | (2.7983) | (2.7983) | (2.7983) | (0.5694) | (0.225) | (0.293) | (0.4274) | (0.45) |
| PTIXW | 0.0391 | 0.0391 | 0.0391 | (9.2857) | 8.7679 | (0.9017) | (0.9017) | (1.9399) | 10.9735 | 5.8765 | (11.3881) | (0.4035) | (0.5143) | (1.2341) | (1.17) |
| RZLT | 8.4464 | 8.4464 | 1.4672 | (0.8037) | (1.1193) | (1.6299) | (2.2945) | 7.6724 | (6.6987) | (2.6516) | (0.5633) | (0.279) | (0.4724) | (0.5719) | (0.54) |
| ANEB | (0.0618) | (0.0618) | (0.0618) | (0.0618) | (0.0618) | (0.0618) | (0.0618) | (0.0618) | (0.0618) | (0.0618) | (0.1688) | (0.4534) | (1.0582) | (2.1793) | (2.07) |
| ERAS | (0.252) | (0.252) | (0.252) | (0.252) | (0.252) | (0.252) | (0.252) | (0.252) | (0.252) | (0.252) | 0.308 | (0.2629) | (0.5308) | (0.3834) | (0.4) |
| FBRX | (0.4081) | (0.4081) | (0.4081) | (0.4081) | (0.4081) | (0.4081) | (1.5113) | (0.5034) | (0.5298) | (0.7075) | 0.3023 | (0.5171) | (0.358) | (0.9199) | (0.87) |
Lumos Pharma and related stocks such as Pardes Biosciences, Shattuck Labs, and Eliem Therapeutics Return On Capital Employed description
My Equities
My Current Equities and Potential Positions
| Lumos Pharma | LUMO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Texas; U.S.A |
| Exchange | NASDAQ Exchange |
USD 4.32
Check out Lumos Pharma Performance and Lumos Pharma Correlation. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Lumos Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.